What the ENTYVIO TV commercial - Your Plan Can Change in Minutes: Chef is about.
The ENTYVIO TV Spot titled 'Your Plan Can Change in Minutes: Chef' features a professional chef who had to face the consequences of her inflammatory bowel disease (IBD) flare-up while in the middle of a dinner service.
The TV spot highlights the unpredictability of IBD and how it can change one's plans in minute's notice. The chef narrates how she was determined to power through her symptoms and complete the service, but eventually had to stop halfway as her health deteriorated. She emphasizes how IBD can affect not only one's body but also their personal and professional life.
The chef then discusses her experience with ENTYVIO, a prescription treatment for adults with moderate to severe ulcerative colitis or Crohn's disease, and how it has helped her manage her IBD symptoms to stay in control of her life. The ENTYVIO TV Spot aims to raise awareness about IBD and the significance of effective treatment in helping patients manage their symptoms and live fulfilling lives.
The TV spot's message is that IBD can be unpredictable and can change one's plans in moments. However, with the right treatment and management plan, patients like the chef in the ENTYVIO TV Spot can continue to live life on their terms.
ENTYVIO TV commercial - Your Plan Can Change in Minutes: Chef produced for
ENTYVIO
was first shown on television on May 3, 2019.
Frequently Asked Questions about entyvio tv spot, 'your plan can change in minutes: chef'
Some patients may feel a benefit within 2-3 weeks of therapy. Typically, it takes up to 6- 8 weeks in ulcerative colitis and 10-14 weeks in Crohn's disease to achieve a significant benefit.
In conclusion, the actress in the Entyvio commercial is the talented Lorraine Toussaint. With her exceptional acting skills and ability to bring characters to life, Toussaint has captivated audiences in various films, television shows, and stage productions.
If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within 30 minutes. 5. Visually inspect the reconstituted ENTYVIO solution for particulate matter and discoloration prior to administration.
The combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with 0.9% Sodium Chloride Injection is a total of 12 hours at room temperature (20° to 25°C [68° to 77°F]) or 24 hours refrigerated (2° to 8°C [36º to 46ºF]).
Vedolizumab Injection. Entyvio® is a brand of vedolizumab. This injection treats ulcerative colitis and Crohn's disease. A healthcare provider will give you this medication in a hospital or clinic setting.
Generic Name: vedolizumab
It works by blocking the actions of a certain natural substance (integrin) in the body. This helps to decrease swelling (inflammation) in the gut, which lessens symptoms and may slow or stop damage from these bowel disorders.
The combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with 0.9% Sodium Chloride Injection is a total of 12 hours at room temperature (20° to 25°C [68° to 77°F]) or 24 hours refrigerated (2° to 8°C [36º to 46ºF]).
MAINTENANCE DOSES STARTING DOSES You will receive ENTYVIO by infusion at Weeks 0, 2, and 6. Starting at Week 14, you'll receive 1 infusion every 8 weeks. After the first year, you'll receive 6 doses each year After the first year, you will receive 6 infusions per year, which is approximately 3 hours.
Your doctor can give you the best information about your treatment course. If after 14 weeks you do not have a therapeutic benefit with Entyvio your doctor may decide to discontinue your treatment.
Entyvio (vedolizumab) is a brand-name prescription medication. It's typically used to treat moderate to severe ulcerative colitis (UC) or Crohn's disease in people who don't have enough improvement from other medications.
Kynteles which is sold globally as Entyvio in more than 60 countries, generated sales of $3.2 billion in FY20. Takeda India, part of the Japanese pharma major Takeda Pharmaceutical Company announced the launch of its blockbuster biologic drug Vedolizumab in India as part of its Gastrointestinal (GI) portfolio.
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.
